For the quarter ending 2025-09-30, AVBP made $41,880K in revenue. -$34,752K in net income. Net profit margin of -82.98%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 32,167 | 27,720 | ||
| General and administrative | 6,149 | 5,903 | ||
| Total operating expenses | 38,316 | 33,623 | ||
| Operating loss | -38,316 | -33,623 | ||
| Interest and investment income | 3,338 | 2,224 | ||
| Net loss | -34,978 | -31,399 | ||
| Unrealized gain on marketable securities | 226 | -1 | ||
| Total other comprehensive gain | 226 | -1 | ||
| Total comprehensive loss | -34,752 | -31,400 | ||
| Earnings per share, basic | -0.83 | -0.9 | ||
| Earnings per share, diluted | -0.83 | -0.9 | ||
| Weighted average number of shares outstanding, basic | 41,912,905 | 35,006,114 | ||
| Weighted average number of shares outstanding, diluted | 41,912,905 | 35,006,114 | ||
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)